Highlights of the AAPS 2024 Summer Scientific Forum
Posted: 21 October 2024 | Drug Target Review | No comments yet
In this episode, we discuss the history of the AAPS Summer Scientific Forum, highlights from the 2024 event, and its goals for the future.
In this podcast episode, titled ‘Highlights of the AAPS 2024 Summer Scientific Forum’, we will be discussing the conferences’ history, as well as its goals for the future.
This conversation features Lynn Kamen, Scientific Officer, Executive Director at BioAgilytix, and Sachin Lohani, Executive Director at Eli Lilly and Company.
Key discussion points:
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
- What differentiates this AAPS conference from both NBC and PharmSci 360
- Key presentation highlights from the 2024 Forum, including:
- The implementation of new technologies for bioanalysis
- Analytical approaches for novel modalities, such as macrocyclic peptides, small proteins, lipid nanoparticles, and charged variants.
- How the Forum fosters community with their scientific attendees
About the speakers
Lynn Kamen, Scientific Officer, Executive Director at BioAgilytix
Sachin Lohani, Executive Director at Eli Lilly and Company
Related topics
Drug Discovery, Research & Development
Related organisations
American Association of Pharmaceutical Scientists (AAPS), BioAgilytix, Eli Lilly and Company
Related people
Lynn Kamen (BioAgilytix), Sachin Lohani (Eli Lilly and Company)